View Item 

Show simple item record

A phase 1 trial of SGNâ CD70A in patients with CD70â positive, metastatic renal cell carcinoma
dc.contributor.authorPal, Sumanta K.
dc.contributor.authorForero‐torres, Andres
dc.contributor.authorThompson, John A.
dc.contributor.authorMorris, John C.
dc.contributor.authorChhabra, Saurabh
dc.contributor.authorHoimes, Christopher J.
dc.contributor.authorVogelzang, Nicholas J.
dc.contributor.authorBoyd, Thomas
dc.contributor.authorBergerot, Paulo G.
dc.contributor.authorAdashek, Jacob J.
dc.contributor.authorLi, Hong
dc.contributor.authorYu, Xuesong
dc.contributor.authorGartner, Elaina M.
dc.contributor.authorCarret, Anne‐sophie
dc.contributor.authorSmith, David C.
dc.date.accessioned2019-04-02T18:11:36Z
dc.date.available2020-06-01T14:50:01Zen
dc.date.issued2019-04-01
dc.identifier.citationPal, Sumanta K.; Forero‐torres, Andres ; Thompson, John A.; Morris, John C.; Chhabra, Saurabh; Hoimes, Christopher J.; Vogelzang, Nicholas J.; Boyd, Thomas; Bergerot, Paulo G.; Adashek, Jacob J.; Li, Hong; Yu, Xuesong; Gartner, Elaina M.; Carret, Anne‐sophie ; Smith, David C. (2019). "A phase 1 trial of SGNâ CD70A in patients with CD70â positive, metastatic renal cell carcinoma." Cancer 125(7): 1124-1132.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/148406
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrenal cell carcinoma
dc.subject.otherphase 1
dc.subject.otherantibodyâ drug conjugate
dc.subject.othercluster of differentiation 70 (CD70)
dc.subject.otherkidney cancer
dc.subject.otherSGNâ CD70A
dc.titleA phase 1 trial of SGNâ CD70A in patients with CD70â positive, metastatic renal cell carcinoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/148406/1/cncr31912.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/148406/2/cncr31912_am.pdf
dc.identifier.doi10.1002/cncr.31912
dc.identifier.sourceCancer
dc.identifier.citedreferenceEscudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab 1 ipilimumab (N1I) v sunitinib (S) for treatmentâ naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PDâ L1 expression subgroups. Ann Oncol. 2017; 28: v621 â v622.
dc.identifier.citedreferenceChoueiri TK, Motzer RJ. Systemic therapy for metastatic renalâ cell carcinoma. N Engl J Med. 2017; 376: 354 â 366.
dc.identifier.citedreferenceDiab A, Tannir N, Cho D, et al. Pivotâ 02: preliminary safety, efficacy and biomarker results from the phase 1/2 study of CDâ 122â biased agonist NKTRâ 214 plus nivolumab in patients with locally advanced/metastatic solid tumors [abstract]. J Immunother Cancer. 2017; 5 ( suppl 2 ): O20.
dc.identifier.citedreferenceSankin A, Hakimi AA, Mikkilineni N, et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 2014; 3: 1485 â 1492.
dc.identifier.citedreferenceGerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883 â 892.
dc.identifier.citedreferenceMotzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for thirdâ line targeted treatment of patients with metastatic renal cell carcinoma: an openâ label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 286 â 296.
dc.identifier.citedreferenceChoueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openâ label, phase 3 trial. Lancet Oncol. 2016; 17: 917 â 927.
dc.identifier.citedreferenceSternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061 â 1068.
dc.identifier.citedreferenceMotzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renalâ cell carcinoma. N Engl J Med. 2007; 356: 115 â 124.
dc.identifier.citedreferenceMa L, Zhou Z, Jia H, et al. Effects of CD70 and CD11a in immune thrombocytopenia patients. J Clin Immunol. 2011; 31: 632 â 642.
dc.identifier.citedreferenceClopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26: 404 â 413.
dc.identifier.citedreferenceEisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228 â 247.
dc.identifier.citedreferencePhillips T, Barr PM, Park SI, et al. A phase 1 trial of SGNâ CD70A in patients with CD70â positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2018.
dc.identifier.citedreferenceSandall S, Anderson M, Jonas M, et al. SGNâ CD70A, a novel and highly potent antiâ CD70 ADC, induces doubleâ strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and nonâ Hodgkin lymphoma (NHL) [abstract]. Cancer Res. 2014; 74 ( suppl ): 2647.
dc.identifier.citedreferenceClaus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012; 72: 3664 â 3676.
dc.identifier.citedreferenceRyan MC, Kostner H, Gordon KA, et al. Targeting pancreatic and ovarian carcinomas using the auristatinâ based antiâ CD70 antibodyâ drug conjugate SGNâ 75. Br J Cancer. 2010; 103: 676 â 684.
dc.identifier.citedreferenceLaw CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for antiâ CD70 antibodyâ drug conjugates. Cancer Res. 2006; 66: 2328 â 2337.
dc.identifier.citedreferenceDiegmann J, Junker K, Gerstmayer B, et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, realâ time RTâ PCR and immunohistochemistry. Eur J Cancer. 2005; 41: 1794 â 1801.
dc.identifier.citedreferenceLens SM, Drillenburg P, den Drijver BF, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol. 1999; 106: 491 â 503.
dc.identifier.citedreferenceMotzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2018; 36 ( 6 suppl ): 578.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr31912.pdf
Size:
312.9KB
Format:
PDF
View/Open
Name:
cncr31912_am.pdf
Size:
251.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.